Language:

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

mSphere, 2019-06, Vol.4 (3), p.e00282-19 [Peer Reviewed Journal]

Copyright © 2019 Tournier et al. ;Copyright © 2019 Tournier et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;Copyright © 2019 Tournier et al. 2019 Tournier et al. ;ISSN: 2379-5042 ;EISSN: 2379-5042 ;DOI: 10.1128/mSphere.00282-19 ;PMID: 31217301

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
Author: Tournier, Jean-Nicolas ; Rougeaux, Clémence ; Biot, Fabrice V ; Goossens, Pierre L
Bradford, Patricia A.
Subjects: Animal models ; Animals ; Anthrax ; Anthrax - immunology ; Anthrax - therapy ; Antibiotics ; Antibodies ; Antibodies, Bacterial ; Antibodies, Bacterial - therapeutic use ; Antibodies, Monoclonal ; Antibodies, Monoclonal - therapeutic use ; Antigens ; Antigens, Bacterial ; Antigens, Bacterial - immunology ; Antitoxins ; Antitoxins - therapeutic use ; Bacillus anthracis ; Bacillus anthracis - immunology ; Bacterial Toxins ; Bacterial Toxins - immunology ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Edema ; Humans ; Immunoglobulins ; Immunotherapy ; Infections ; Kinases ; Life Sciences ; Monoclonal antibodies ; Opinion/Hypothesis ; Patients ; Protective antigen ; Respiratory Tract Infections ; Respiratory Tract Infections - immunology ; Respiratory Tract Infections - therapy ; Sepsis ; Studies ; Therapeutics and Prevention ; Toxins ; Vaccines
Is Part Of: mSphere, 2019-06, Vol.4 (3), p.e00282-19
Description: Inhalational anthrax caused by , a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. We argue that inductive reasoning may induce therapeutic bias. We identified anthrax animal model analysis as another bias. Further studies are needed to assess the benefit of anti-PA antibodies in the treatment of inhalational anthrax, while a clearer consensus should be established around what evidence should be proven in an anthrax model.
Publisher: United States: American Society for Microbiology
Language: English
Identifier: ISSN: 2379-5042
EISSN: 2379-5042
DOI: 10.1128/mSphere.00282-19
PMID: 31217301
Source: DOAJ Directory of Open Access Journals
AUTh Library subscriptions: ProQuest Central
Hyper Article en Ligne (HAL) (Open Access)
MEDLINE
PubMed Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

Searching Remote Databases, Please Wait